Contact Information
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
PediatricsInfectious Diseases700 Children’s DrColumbus, OH 43205 (map)
Learn more about Kevin A. Cassady
Biography
Kevin A. Cassady, MD, is a physician for the Division of Infectious Diseases at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and an associate professor of pediatrics at The Ohio State University College of Medicine. Dr. Cassady received his bachelor’s degree from Georgetown University, his medical degree from the University of Alabama School of Medicine, and his pediatric specialty training at University of Washington in Seattle. Dr. Cassady completed a post-doctoral fellowship in Molecular Virology in Dr. Bernard Roizman’s lab at the University of Chicago and then completed his pediatric infectious disease training at the University of Alabama at Birmingham (UAB) where he joined the Pediatric Infectious Disease Faculty. Dr. Cassady is an Associate Professor at the Research Institute at Nationwide Children’s Hospital and in the Ohio State University Department of Pediatrics. He is a member of both the Center for Childhood Cancer and the Division of Pediatric Infectious Diseases.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Infectious Diseases
Physician Team
Center for Childhood Cancer
Principal Investigator
Infectious Diseases Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Infectious Diseases
Awards, Honors & Organizations
Listed, Best Doctors in America
Research
Lab(s)
Center for Childhood Cancer
My research focuses on how Herpes Simplex Virus (HSV) induces and modulates the antiviral immune response. By understanding how the cell restricts virus replication we have developed a recombinant HSV that selectively replicates in tumor cells and can be used safely to treat brain tumors. We are now advancing this virus into clinical trials and are investigating ways to improve virotherapy by harnessing the antiviral immune response and directing it against the tumor. Publications
Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, Markert JM. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clin Cancer Res. 2022 Feb 1; 28: 498-506.
Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. J Immunother Cancer. 2021 Oct; 9:
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019 Jun 28; 13: 14-21.
Lee J, Ghonime MG, Wang R, Cassady KA. The Antiviral Apparatus: STING and Oncolytic Virus Restriction. Mol Ther Oncolytics. 2019 Jun 28; 13: 7-13.
Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics. 2018 Dec 21; 11: 62-74.
Ghonime M, Cassady KA. Combination Therapy using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunol Res. 2018 Oct 23;
Erdem G, Watson JR, Hunt WG, Young C, Tomatis Souverbielle C, Honegger JR, Cassady KA, Ilgenfritz M, Napolitano S, Koranyi K. Clinical and Radiologic Manifestations of Bone Infection in Children with Cat Scratch Disease. J Pediatr. 2018 Oct; 201: 274-280.e12.
Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and ??134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol. 2018 Feb; 11: 86-93.
Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM. Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Mol Ther Oncolytics. 2017 Jun 16; 5: 1-10.
View More Publications
Education
Date of Appointment at Nationwide Children’s Hospital: 07/06/2015
Board Certifications
Pediatric Infectious Diseases Pediatrics
Fellowship
Children’s of Alabama
Date Completed: 03/31/1999
Fellowship
Children’s of Alabama and University of Alabama at
Date Completed: 07/31/1995
Residency
Seattle Children’s Hospital
Date Completed: 06/30/1994
Medical School
University of Alabama
Date Completed: 06/30/1991
Contact Information
Pediatrics
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
Infectious Diseases700 Children's DrColumbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
PediatricsInfectious Diseases700 Children’s DrColumbus, OH 43205 (map)
Learn more about Kevin A. Cassady
Biography
Kevin A. Cassady, MD, is a physician for the Division of Infectious Diseases at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and an associate professor of pediatrics at The Ohio State University College of Medicine. Dr. Cassady received his bachelor’s degree from Georgetown University, his medical degree from the University of Alabama School of Medicine, and his pediatric specialty training at University of Washington in Seattle. Dr. Cassady completed a post-doctoral fellowship in Molecular Virology in Dr. Bernard Roizman’s lab at the University of Chicago and then completed his pediatric infectious disease training at the University of Alabama at Birmingham (UAB) where he joined the Pediatric Infectious Disease Faculty. Dr. Cassady is an Associate Professor at the Research Institute at Nationwide Children’s Hospital and in the Ohio State University Department of Pediatrics. He is a member of both the Center for Childhood Cancer and the Division of Pediatric Infectious Diseases.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Infectious Diseases
Physician Team
Center for Childhood Cancer
Principal Investigator
Infectious Diseases Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Infectious Diseases
Awards, Honors & Organizations
Listed, Best Doctors in America
Research
Lab(s)
Center for Childhood Cancer
My research focuses on how Herpes Simplex Virus (HSV) induces and modulates the antiviral immune response. By understanding how the cell restricts virus replication we have developed a recombinant HSV that selectively replicates in tumor cells and can be used safely to treat brain tumors. We are now advancing this virus into clinical trials and are investigating ways to improve virotherapy by harnessing the antiviral immune response and directing it against the tumor. Publications
Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, Markert JM. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clin Cancer Res. 2022 Feb 1; 28: 498-506.
Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. J Immunother Cancer. 2021 Oct; 9:
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019 Jun 28; 13: 14-21.
Lee J, Ghonime MG, Wang R, Cassady KA. The Antiviral Apparatus: STING and Oncolytic Virus Restriction. Mol Ther Oncolytics. 2019 Jun 28; 13: 7-13.
Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics. 2018 Dec 21; 11: 62-74.
Ghonime M, Cassady KA. Combination Therapy using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunol Res. 2018 Oct 23;
Erdem G, Watson JR, Hunt WG, Young C, Tomatis Souverbielle C, Honegger JR, Cassady KA, Ilgenfritz M, Napolitano S, Koranyi K. Clinical and Radiologic Manifestations of Bone Infection in Children with Cat Scratch Disease. J Pediatr. 2018 Oct; 201: 274-280.e12.
Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and ??134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol. 2018 Feb; 11: 86-93.
Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM. Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Mol Ther Oncolytics. 2017 Jun 16; 5: 1-10.
View More Publications
Education
Date of Appointment at Nationwide Children’s Hospital: 07/06/2015
Board Certifications
Pediatric Infectious Diseases Pediatrics
Fellowship
Children’s of Alabama
Date Completed: 03/31/1999
Fellowship
Children’s of Alabama and University of Alabama at
Date Completed: 07/31/1995
Residency
Seattle Children’s Hospital
Date Completed: 06/30/1994
Medical School
University of Alabama
Date Completed: 06/30/1991
Contact Information
Pediatrics
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
Infectious Diseases700 Children's DrColumbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
PediatricsInfectious Diseases700 Children’s DrColumbus, OH 43205 (map)
Learn more about Kevin A. Cassady
Contact Information
- Call us at:
- (614) 722-4450
- Fax us at:
- (614) 722-4458
- PediatricsInfectious Diseases700 Children’s DrColumbus, OH 43205 (map)
Learn more about Kevin A. Cassady
Biography
Kevin A. Cassady, MD, is a physician for the Division of Infectious Diseases at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and an associate professor of pediatrics at The Ohio State University College of Medicine. Dr. Cassady received his bachelor’s degree from Georgetown University, his medical degree from the University of Alabama School of Medicine, and his pediatric specialty training at University of Washington in Seattle. Dr. Cassady completed a post-doctoral fellowship in Molecular Virology in Dr. Bernard Roizman’s lab at the University of Chicago and then completed his pediatric infectious disease training at the University of Alabama at Birmingham (UAB) where he joined the Pediatric Infectious Disease Faculty. Dr. Cassady is an Associate Professor at the Research Institute at Nationwide Children’s Hospital and in the Ohio State University Department of Pediatrics. He is a member of both the Center for Childhood Cancer and the Division of Pediatric Infectious Diseases.
Biography
Kevin A. Cassady, MD, is a physician for the Division of Infectious Diseases at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and an associate professor of pediatrics at The Ohio State University College of Medicine. Dr. Cassady received his bachelor’s degree from Georgetown University, his medical degree from the University of Alabama School of Medicine, and his pediatric specialty training at University of Washington in Seattle. Dr. Cassady completed a post-doctoral fellowship in Molecular Virology in Dr. Bernard Roizman’s lab at the University of Chicago and then completed his pediatric infectious disease training at the University of Alabama at Birmingham (UAB) where he joined the Pediatric Infectious Disease Faculty. Dr. Cassady is an Associate Professor at the Research Institute at Nationwide Children’s Hospital and in the Ohio State University Department of Pediatrics. He is a member of both the Center for Childhood Cancer and the Division of Pediatric Infectious Diseases.
Biography
Kevin A. Cassady, MD, is a physician for the Division of Infectious Diseases at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and an associate professor of pediatrics at The Ohio State University College of Medicine. Dr. Cassady received his bachelor’s degree from Georgetown University, his medical degree from the University of Alabama School of Medicine, and his pediatric specialty training at University of Washington in Seattle. Dr. Cassady completed a post-doctoral fellowship in Molecular Virology in Dr. Bernard Roizman’s lab at the University of Chicago and then completed his pediatric infectious disease training at the University of Alabama at Birmingham (UAB) where he joined the Pediatric Infectious Disease Faculty. Dr. Cassady is an Associate Professor at the Research Institute at Nationwide Children’s Hospital and in the Ohio State University Department of Pediatrics. He is a member of both the Center for Childhood Cancer and the Division of Pediatric Infectious Diseases.
Kevin A. Cassady, MD, is a physician for the Division of Infectious Diseases at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and an associate professor of pediatrics at The Ohio State University College of Medicine. Dr. Cassady received his bachelor’s degree from Georgetown University, his medical degree from the University of Alabama School of Medicine, and his pediatric specialty training at University of Washington in Seattle. Dr. Cassady completed a post-doctoral fellowship in Molecular Virology in Dr. Bernard Roizman’s lab at the University of Chicago and then completed his pediatric infectious disease training at the University of Alabama at Birmingham (UAB) where he joined the Pediatric Infectious Disease Faculty. Dr. Cassady is an Associate Professor at the Research Institute at Nationwide Children’s Hospital and in the Ohio State University Department of Pediatrics. He is a member of both the Center for Childhood Cancer and the Division of Pediatric Infectious Diseases.
Kevin A. Cassady, MD, is a physician for the Division of Infectious Diseases at Nationwide Children’s Hospital, a principal investigator for the Center for Childhood Cancer at The Research Institute at Nationwide Children’s Hospital and an associate professor of pediatrics at The Ohio State University College of Medicine.
Dr. Cassady received his bachelor’s degree from Georgetown University, his medical degree from the University of Alabama School of Medicine, and his pediatric specialty training at University of Washington in Seattle. Dr. Cassady completed a post-doctoral fellowship in Molecular Virology in Dr. Bernard Roizman’s lab at the University of Chicago and then completed his pediatric infectious disease training at the University of Alabama at Birmingham (UAB) where he joined the Pediatric Infectious Disease Faculty. Dr. Cassady is an Associate Professor at the Research Institute at Nationwide Children’s Hospital and in the Ohio State University Department of Pediatrics. He is a member of both the Center for Childhood Cancer and the Division of Pediatric Infectious Diseases.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
- Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Infectious Diseases
Physician Team
Center for Childhood Cancer
Principal Investigator
Infectious Diseases Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Infectious Diseases
Academic and Clinical Areas
Infectious Diseases
Physician Team
Center for Childhood Cancer
Principal Investigator
Infectious Diseases Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Infectious Diseases
Academic and Clinical Areas
Infectious Diseases
Physician Team
Center for Childhood Cancer
Principal Investigator
Infectious Diseases Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Infectious Diseases
Infectious Diseases
Physician Team
Center for Childhood Cancer
Principal Investigator
Infectious Diseases Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Infectious Diseases
- Infectious Diseases
- Physician Team
- Center for Childhood Cancer
- Principal Investigator
- Infectious Diseases Fellowship
- Faculty
- Primary Department
- Pediatrics
- Primary Section
- Infectious Diseases
Awards, Honors & Organizations
Listed, Best Doctors in America
Awards, Honors & Organizations
Listed, Best Doctors in America
Awards, Honors & Organizations
Listed, Best Doctors in America
Listed, Best Doctors in America
- Listed, Best Doctors in America
Research
Lab(s)
Center for Childhood Cancer
My research focuses on how Herpes Simplex Virus (HSV) induces and modulates the antiviral immune response. By understanding how the cell restricts virus replication we have developed a recombinant HSV that selectively replicates in tumor cells and can be used safely to treat brain tumors. We are now advancing this virus into clinical trials and are investigating ways to improve virotherapy by harnessing the antiviral immune response and directing it against the tumor. Publications
Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, Markert JM. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clin Cancer Res. 2022 Feb 1; 28: 498-506.
Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. J Immunother Cancer. 2021 Oct; 9:
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019 Jun 28; 13: 14-21.
Lee J, Ghonime MG, Wang R, Cassady KA. The Antiviral Apparatus: STING and Oncolytic Virus Restriction. Mol Ther Oncolytics. 2019 Jun 28; 13: 7-13.
Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics. 2018 Dec 21; 11: 62-74.
Ghonime M, Cassady KA. Combination Therapy using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunol Res. 2018 Oct 23;
Erdem G, Watson JR, Hunt WG, Young C, Tomatis Souverbielle C, Honegger JR, Cassady KA, Ilgenfritz M, Napolitano S, Koranyi K. Clinical and Radiologic Manifestations of Bone Infection in Children with Cat Scratch Disease. J Pediatr. 2018 Oct; 201: 274-280.e12.
Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and ??134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol. 2018 Feb; 11: 86-93.
Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM. Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Mol Ther Oncolytics. 2017 Jun 16; 5: 1-10.
View More Publications
Research
Lab(s)
Center for Childhood Cancer
My research focuses on how Herpes Simplex Virus (HSV) induces and modulates the antiviral immune response. By understanding how the cell restricts virus replication we have developed a recombinant HSV that selectively replicates in tumor cells and can be used safely to treat brain tumors. We are now advancing this virus into clinical trials and are investigating ways to improve virotherapy by harnessing the antiviral immune response and directing it against the tumor. Publications
Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, Markert JM. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clin Cancer Res. 2022 Feb 1; 28: 498-506.
Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. J Immunother Cancer. 2021 Oct; 9:
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019 Jun 28; 13: 14-21.
Lee J, Ghonime MG, Wang R, Cassady KA. The Antiviral Apparatus: STING and Oncolytic Virus Restriction. Mol Ther Oncolytics. 2019 Jun 28; 13: 7-13.
Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics. 2018 Dec 21; 11: 62-74.
Ghonime M, Cassady KA. Combination Therapy using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunol Res. 2018 Oct 23;
Erdem G, Watson JR, Hunt WG, Young C, Tomatis Souverbielle C, Honegger JR, Cassady KA, Ilgenfritz M, Napolitano S, Koranyi K. Clinical and Radiologic Manifestations of Bone Infection in Children with Cat Scratch Disease. J Pediatr. 2018 Oct; 201: 274-280.e12.
Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and ??134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol. 2018 Feb; 11: 86-93.
Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM. Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Mol Ther Oncolytics. 2017 Jun 16; 5: 1-10.
View More Publications
Research
Lab(s)
Center for Childhood Cancer
My research focuses on how Herpes Simplex Virus (HSV) induces and modulates the antiviral immune response. By understanding how the cell restricts virus replication we have developed a recombinant HSV that selectively replicates in tumor cells and can be used safely to treat brain tumors. We are now advancing this virus into clinical trials and are investigating ways to improve virotherapy by harnessing the antiviral immune response and directing it against the tumor. Publications
Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, Markert JM. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clin Cancer Res. 2022 Feb 1; 28: 498-506.
Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. J Immunother Cancer. 2021 Oct; 9:
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019 Jun 28; 13: 14-21.
Lee J, Ghonime MG, Wang R, Cassady KA. The Antiviral Apparatus: STING and Oncolytic Virus Restriction. Mol Ther Oncolytics. 2019 Jun 28; 13: 7-13.
Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics. 2018 Dec 21; 11: 62-74.
Ghonime M, Cassady KA. Combination Therapy using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunol Res. 2018 Oct 23;
Erdem G, Watson JR, Hunt WG, Young C, Tomatis Souverbielle C, Honegger JR, Cassady KA, Ilgenfritz M, Napolitano S, Koranyi K. Clinical and Radiologic Manifestations of Bone Infection in Children with Cat Scratch Disease. J Pediatr. 2018 Oct; 201: 274-280.e12.
Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and ??134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol. 2018 Feb; 11: 86-93.
Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM. Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Mol Ther Oncolytics. 2017 Jun 16; 5: 1-10.
View More Publications
Lab(s)
Center for Childhood Cancer
My research focuses on how Herpes Simplex Virus (HSV) induces and modulates the antiviral immune response. By understanding how the cell restricts virus replication we have developed a recombinant HSV that selectively replicates in tumor cells and can be used safely to treat brain tumors. We are now advancing this virus into clinical trials and are investigating ways to improve virotherapy by harnessing the antiviral immune response and directing it against the tumor. Publications
Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, Markert JM. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clin Cancer Res. 2022 Feb 1; 28: 498-506.
Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. J Immunother Cancer. 2021 Oct; 9:
Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019 Jun 28; 13: 14-21.
Lee J, Ghonime MG, Wang R, Cassady KA. The Antiviral Apparatus: STING and Oncolytic Virus Restriction. Mol Ther Oncolytics. 2019 Jun 28; 13: 7-13.
Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics. 2018 Dec 21; 11: 62-74.
Ghonime M, Cassady KA. Combination Therapy using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunol Res. 2018 Oct 23;
Erdem G, Watson JR, Hunt WG, Young C, Tomatis Souverbielle C, Honegger JR, Cassady KA, Ilgenfritz M, Napolitano S, Koranyi K. Clinical and Radiologic Manifestations of Bone Infection in Children with Cat Scratch Disease. J Pediatr. 2018 Oct; 201: 274-280.e12.
Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and ??134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol. 2018 Feb; 11: 86-93.
Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM. Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Mol Ther Oncolytics. 2017 Jun 16; 5: 1-10.
View More Publications
Lab(s)
Center for Childhood Cancer
My research focuses on how Herpes Simplex Virus (HSV) induces and modulates the antiviral immune response. By understanding how the cell restricts virus replication we have developed a recombinant HSV that selectively replicates in tumor cells and can be used safely to treat brain tumors. We are now advancing this virus into clinical trials and are investigating ways to improve virotherapy by harnessing the antiviral immune response and directing it against the tumor.
Lab(s)
Center for Childhood Cancer
Center for Childhood Cancer
Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, Markert JM. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clin Cancer Res. 2022 Feb 1; 28: 498-506. Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. J Immunother Cancer. 2021 Oct; 9: Auletta JJ, Sánchez PJ, Meyer EK, O'Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4. Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019 Jun 28; 13: 14-21. Lee J, Ghonime MG, Wang R, Cassady KA. The Antiviral Apparatus: STING and Oncolytic Virus Restriction. Mol Ther Oncolytics. 2019 Jun 28; 13: 7-13. Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics. 2018 Dec 21; 11: 62-74. Ghonime M, Cassady KA. Combination Therapy using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunol Res. 2018 Oct 23; Erdem G, Watson JR, Hunt WG, Young C, Tomatis Souverbielle C, Honegger JR, Cassady KA, Ilgenfritz M, Napolitano S, Koranyi K. Clinical and Radiologic Manifestations of Bone Infection in Children with Cat Scratch Disease. J Pediatr. 2018 Oct; 201: 274-280.e12. Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and ??134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol. 2018 Feb; 11: 86-93. Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM. Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Mol Ther Oncolytics. 2017 Jun 16; 5: 1-10.
View More Publications
- Miller KE, Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, Leavenworth JW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER, Markert JM. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clin Cancer Res. 2022 Feb 1; 28: 498-506.
- Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. J Immunother Cancer. 2021 Oct; 9:
- Auletta JJ, Sánchez PJ, Meyer EK, O’Donnell LC, Cassady KA, Ouellette CP, Hecht S, Diaz A, Pavlek LR, Salamon DP, Gallagher CL, Bradbury H, Welfley SL, Magers J, Armbruster DL, Lamb MG, Nakkula RJ, Bosse K, Lee DA. Adjuvant haploidentical virus-specific T lymphocytes for treatment of disseminated adenovirus infection in a premature infant. J Allergy Clin Immunol. 2019 Aug; 144: 594-597.e4.
- Pearl TM, Markert JM, Cassady KA, Ghonime MG. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019 Jun 28; 13: 14-21.
- Lee J, Ghonime MG, Wang R, Cassady KA. The Antiviral Apparatus: STING and Oncolytic Virus Restriction. Mol Ther Oncolytics. 2019 Jun 28; 13: 7-13.
- Denton NL, Chen CY, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang PY, Srinivas R, Cassady KA, Goins WF, Cripe TP. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics. 2018 Dec 21; 11: 62-74.
- Ghonime M, Cassady KA. Combination Therapy using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunol Res. 2018 Oct 23;
- Erdem G, Watson JR, Hunt WG, Young C, Tomatis Souverbielle C, Honegger JR, Cassady KA, Ilgenfritz M, Napolitano S, Koranyi K. Clinical and Radiologic Manifestations of Bone Infection in Children with Cat Scratch Disease. J Pediatr. 2018 Oct; 201: 274-280.e12.
- Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and ??134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol. 2018 Feb; 11: 86-93.
- Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM. Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Mol Ther Oncolytics. 2017 Jun 16; 5: 1-10.
Education
Date of Appointment at Nationwide Children’s Hospital: 07/06/2015
Board Certifications
Pediatric Infectious Diseases Pediatrics
Fellowship
Children’s of Alabama
Date Completed: 03/31/1999
Fellowship
Children’s of Alabama and University of Alabama at
Date Completed: 07/31/1995
Residency
Seattle Children’s Hospital
Date Completed: 06/30/1994
Medical School
University of Alabama
Date Completed: 06/30/1991
Education
Date of Appointment at Nationwide Children’s Hospital: 07/06/2015
Board Certifications
Pediatric Infectious Diseases Pediatrics
Fellowship
Children’s of Alabama
Date Completed: 03/31/1999
Fellowship
Children’s of Alabama and University of Alabama at
Date Completed: 07/31/1995
Residency
Seattle Children’s Hospital
Date Completed: 06/30/1994
Medical School
University of Alabama
Date Completed: 06/30/1991
Education
Date of Appointment at Nationwide Children’s Hospital: 07/06/2015
Board Certifications
Pediatric Infectious Diseases Pediatrics
Fellowship
Children’s of Alabama
Date Completed: 03/31/1999
Fellowship
Children’s of Alabama and University of Alabama at
Date Completed: 07/31/1995
Residency
Seattle Children’s Hospital
Date Completed: 06/30/1994
Medical School
University of Alabama
Date Completed: 06/30/1991
Date of Appointment at Nationwide Children’s Hospital: 07/06/2015
Board Certifications
Pediatric Infectious Diseases Pediatrics
Fellowship
Children’s of Alabama
Date Completed: 03/31/1999
Fellowship
Children’s of Alabama and University of Alabama at
Date Completed: 07/31/1995
Residency
Seattle Children’s Hospital
Date Completed: 06/30/1994
Medical School
University of Alabama
Date Completed: 06/30/1991
Date of Appointment at Nationwide Children’s Hospital: 07/06/2015
Board Certifications
Pediatric Infectious Diseases Pediatrics
Fellowship
Children’s of Alabama
Date Completed: 03/31/1999
Fellowship
Children’s of Alabama and University of Alabama at
Date Completed: 07/31/1995
Residency
Seattle Children’s Hospital
Date Completed: 06/30/1994
Medical School
University of Alabama
Date Completed: 06/30/1991
- Pediatric Infectious Diseases
- Pediatrics
Contact Information
Pediatrics
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
Infectious Diseases700 Children's DrColumbus, OH 43205 (map)
Contact Information
Pediatrics
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
Infectious Diseases700 Children's DrColumbus, OH 43205 (map)
Contact Information
Pediatrics
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
Infectious Diseases700 Children's DrColumbus, OH 43205 (map)
Pediatrics
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
Infectious Diseases700 Children's DrColumbus, OH 43205 (map)
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
Infectious Diseases700 Children's DrColumbus, OH 43205 (map)
Call us at: (614) 722-4450
Fax us at: (614) 722-4458
Infectious Diseases700 Children's DrColumbus, OH 43205 (map)
- Call us at:
- (614) 722-4450
- Fax us at:
- (614) 722-4458
- Infectious Diseases700 Children’s DrColumbus, OH 43205 (map)
